Zhao Li-Ni, Wang Ping, Liu Yun-Hui, Cai Heng, Ma Jun, Liu Li-Bo, Xi Zhuo, Li Zhi-Qing, Liu Xiao-Bai, Xue Yi-Xue
Department of Neurobiology, College of Basic Medicine, China Medical University, Shenyang 110122, People's Republic of China; Institute of Pathology and Pathophysiology, China Medical University, Shenyang 110122, People's Republic of China.
Department of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China; Liaoning Research Center for Translational Medicine in Nervous System Disease, Shenyang 110004, People's Republic of China.
Cell Signal. 2017 Jan;30:142-153. doi: 10.1016/j.cellsig.2016.09.007. Epub 2016 Sep 28.
Malignant glioma is undoubtedly the most vascularized tumor of central nervous system. Angiogenesis, playing a predominant role in tumor progression, is widely considered as a key point of tumor treatment. The aim of this study was to investigate the potential effects of miR-383 on proliferation, migration, tube formation and angiogenesis of glioma-exposed endothelial cells (GECs) in vitro and to further elucidate its possible molecular mechanisms. The expression of miR-383 in GECs was significantly downregulated compared with that in normal endothelial cells (ECs). Overexpression of miR-383 dramatically inhibited the proliferation, migration, tube formation and spheroid-based angiogenesis of GECs in vitro. Dual-luciferase reporter results demonstrated vascular endothelial growth factor (VEGF) is a target gene of miR-383. Furthermore, overexpression or silencing of either miR-383 or VEGF was performed simultaneously to further clarify that miR-383 inhibited proliferation, migration and angiogenesis of GECs in vitro by targeting VEGF. Finally, VEGF/VEGFR2-mediated FAK and Src signaling pathways might contribute to anti-angiogenesis of GECs. In conclusion, our present study indicated that miR-383 inhibits proliferation, migration and angiogenesis of GECs in vitro via VEGF/VEGFR2-mediated FAK and Src signaling pathways, which would draw growing attention to miR-383c as a potential therapeutical target of glioma.
恶性胶质瘤无疑是中枢神经系统中血管生成最为丰富的肿瘤。血管生成在肿瘤进展中起主要作用,被广泛认为是肿瘤治疗的关键靶点。本研究旨在探讨miR-383对体外培养的胶质瘤相关内皮细胞(GECs)增殖、迁移、管腔形成和血管生成的潜在影响,并进一步阐明其可能的分子机制。与正常内皮细胞(ECs)相比,GECs中miR-383的表达显著下调。miR-383的过表达显著抑制了体外培养的GECs的增殖、迁移、管腔形成和基于球体的血管生成。双荧光素酶报告基因结果表明血管内皮生长因子(VEGF)是miR-383的靶基因。此外,同时对miR-383或VEGF进行过表达或沉默,以进一步阐明miR-383通过靶向VEGF抑制体外培养的GECs的增殖、迁移和血管生成。最后,VEGF/VEGFR2介导的FAK和Src信号通路可能参与了GECs的抗血管生成作用。总之,我们目前的研究表明,miR-383通过VEGF/VEGFR2介导的FAK和Src信号通路抑制体外培养的GECs的增殖、迁移和血管生成,这将使miR-383作为胶质瘤潜在治疗靶点受到越来越多的关注。